Orbital myositis in a rheumatoid arthritis patient during etanercept treatment.
Caramaschi
P
P
Biasi
D
D
Carletto
A
A
Bambara
L M
LM
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D009801:Oculomotor Muscles / Q000473:pathology; D016727:Orbital Pseudotumor / Q000209:etiology* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D006886:Hydroxychloroquine; D000068800:Etanercept; D008775:Methylprednisolone; D008727:Methotrexate